Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Van Laethem JL, Riess H, Jassem J, Haas M, Martens UM, Weekes C, Peeters M, Ross P, Bridgewater J, Melichar B, Cascinu S, Saramak P, Michl P, Van Brummelen D, Zaniboni A, Schmiegel W, Dueland S, Giurescu M, Garosi VL, Roth K, Schulz A, Seidel H, Rajagopalan P, Teufel M, Childs BH. Van Laethem JL, et al. Among authors: cascinu s. Target Oncol. 2017 Feb;12(1):97-109. doi: 10.1007/s11523-016-0469-y. Target Oncol. 2017. PMID: 27975152 Clinical Trial.
High-versus low-dose levo-leucovorin as a modulator of 5-fluorouracil in advanced colorectal cancer: a 'GISCAD' phase III study. Italian Group for the Study of Digestive Tract Cancer.
Labianca R, Cascinu S, Frontini L, Barni S, Fiorentini G, Comella G, Zaniboni A, Gottardi O, Arnoldi E, Oliani C, Duro M, Pavanato G, Martignoni G, Raina A, Piazza E, Dallavalle G, Valsecchi R, Pancera G, Luporini G. Labianca R, et al. Among authors: cascinu s. Ann Oncol. 1997 Feb;8(2):169-74. doi: 10.1023/a:1008200713533. Ann Oncol. 1997. PMID: 9093726 Free article. Clinical Trial.
Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer.
Cascinu S, Labianca R, Alessandroni P, Marcellini M, Silva RR, Pancera G, Testa E, Martignoni G, Barni S, Frontini L, Zaniboni A, Luporini G, Cellerino R, Catalano G. Cascinu S, et al. J Clin Oncol. 1997 Nov;15(11):3313-9. doi: 10.1200/JCO.1997.15.11.3313. J Clin Oncol. 1997. PMID: 9363860 Clinical Trial.
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Cascinu S, Frontini L, Labianca R, Catalano V, Barni S, Graiff C, Picone G, Farinati E, Zonato S, Pessi MA, Curti C, Catalano G. Cascinu S, et al. Ann Oncol. 2000 Oct;11(10):1309-11. doi: 10.1023/a:1008393010472. Ann Oncol. 2000. PMID: 11106121 Free article.
The value of oxaliplatin in combination with continuous infusion +/- bolus 5-fluorouracil and levo-folinic acid in metastatic colorectal cancer progressing after 5FU-based chemotherapy: a GISCAD (Italian Group for the Study of Digestive Tract) cancer phase II trial.
Mosconi S, Cascinu S, Zaniboni A, Catalano V, Giordani P, Beretta GD, Martignoni G, Pancera G, Baldelli AM, Poletti P, Curti C, Labianca R. Mosconi S, et al. Among authors: cascinu s. Tumori. 2000 Nov-Dec;86(6):465-9. doi: 10.1177/030089160008600606. Tumori. 2000. PMID: 11218187 Clinical Trial.
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Cascinu S, Labianca R, Catalano V, Barni S, Ferraù F, Beretta GD, Frontini L, Foa P, Pancera G, Priolo D, Graziano F, Mare M, Catalano G. Cascinu S, et al. Ann Oncol. 2003 Feb;14(2):205-8. doi: 10.1093/annonc/mdg061. Ann Oncol. 2003. PMID: 12562645 Free article. Clinical Trial.
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patients.
Scartozzi M, Sobrero A, Gasparini G, Berardi R, Catalano V, Graziano F, Barni S, Zaniboni A, Beretta GD, Labianca R, Cascinu S; Italian Group for the Study of Digestive Tract Cancer. Scartozzi M, et al. Among authors: cascinu s. Oncology. 2005;68(2-3):212-6. doi: 10.1159/000086776. Epub 2005 Jul 7. Oncology. 2005. PMID: 16015036
657 results